Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)
Sponsor: GlaxoSmithKline
Summary
The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.
Official title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants 40 to 80 Years of Age With Moderate to Very Severe COPD (PERSIST COPD-2)
Key Details
Gender
All
Age Range
40 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
624
Start Date
2026-09-11
Completion Date
2030-03-15
Last Updated
2026-09-25
Healthy Volunteers
No
Conditions
Interventions
GSK5784283
GSK5784283 will be administered.
Placebo
Placebo will be administered.
Standard of care
Standard of care will be administered.
Locations (4)
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Tampa, Florida, United States
GSK Investigational Site
Rapid City, South Dakota, United States
GSK Investigational Site
West Point, Utah, United States